^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    YH012

    i
    Other names: YH012
    Company:
    Biocytogen, Radiance Biopharma
    Drug class:
    HER2-targeted antibody-drug conjugate, Tubulin inhibitor, TROP-2-targeted antibody-drug conjugate
    Related drugs:
    almost2years
    A first-in-class anti-HER2/TROP2 bispecific antibody-drug conjugate (YH012) exhibits potent anti-tumor efficacy (AACR 2023)
    Moreover, YH012 exhibited superior anti-tumor efficacy than benchmark antibodies in both HER2-positive and HER2-low xenograft models, indicating that YH012 has a potent and broad therapeutic effect. In summary, YH012 has the advantages of increased potency, tissue specificity, and reduced toxicity as a novel BsADC that can be further exploited to treat HER2 and TROP2 co-expressing tumors, especially HER2-low tumors.
    Clinical
    |
    TACSTD2 (Tumor Associated Calcium Signal Transducer 2)
    |
    HER-2 positive • HER-2 expression • HER-2 underexpression • TROP2 expression
    |
    YH012